


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:34Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407818" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407818</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>adipocyte</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Adipocyte</journal-id><journal-id journal-id-type="iso-abbrev">Adipocyte</journal-id><journal-id journal-id-type="pmc-domain-id">1988</journal-id><journal-id journal-id-type="pmc-domain">adipocyte</journal-id><journal-title-group><journal-title>Adipocyte</journal-title></journal-title-group><issn pub-type="ppub">2162-3945</issn><issn pub-type="epub">2162-397X</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407818</article-id><article-id pub-id-type="pmcid-ver">PMC12407818.1</article-id><article-id pub-id-type="pmcaid">12407818</article-id><article-id pub-id-type="pmcaiid">12407818</article-id><article-id pub-id-type="pmid">40878808</article-id><article-id pub-id-type="doi">10.1080/21623945.2025.2548787</article-id><article-id pub-id-type="publisher-id">2548787</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Development of vascularized adipose organoids from PBMSCs and their application in evaluating Celastrol&#8217;s effects</article-title><alt-title alt-title-type="left-running-head">S. LI ET AL.</alt-title><alt-title alt-title-type="right-running-head">ADIPOCYTE</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="S">Sen</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0003" ref-type="author-notes">
<sup>*</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab-term="Conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/" vocab-term="Methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/" vocab-term="Validation">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/" vocab-term="Writing &#x2013; original draft">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kan</surname><given-names initials="F">Fangming</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="an0003" ref-type="author-notes">
<sup>*</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab-term="Conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/" vocab-term="Methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/" vocab-term="Validation">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/" vocab-term="Writing &#x2013; original draft">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ji</surname><given-names initials="S">Shuhui</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/" vocab-term="Validation">Validation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cao</surname><given-names initials="D">Dingding</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/" vocab-term="Validation">Validation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="H">Haiyang</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref><xref rid="aff0006" ref-type="aff">
<sup>f</sup>
</xref><xref rid="aff0007" ref-type="aff">
<sup>g</sup>
</xref><xref rid="an0001" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-term="Supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-term="Writing &#x2013; review &amp; editing">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="J">Jianxin</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0008" ref-type="aff">
<sup>h</sup>
</xref><xref rid="an0002" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-term="Supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-term="Writing &#x2013; review &amp; editing">Writing &#8211; review &amp; editing</role></contrib><aff id="aff0001"><label>a</label>Department of Biochemistry and Immunology, <institution-wrap><institution>Capital Institute of Pediatrics</institution></institution-wrap>, <city>Beijing</city>, <country>China</country></aff><aff id="aff0002"><label>b</label>Beijing Municipal Key Laboratory of Child Development and Nutriomics, <institution-wrap><institution>Capital Institute of Pediatrics</institution></institution-wrap>, <city>Beijing</city>, <country>China</country></aff><aff id="aff0003"><label>c</label>College of Life Sciences, <institution-wrap><institution>University of Chinese Academy of Sciences</institution></institution-wrap>, <city>Beijing</city>, <country>China</country></aff><aff id="aff0004"><label>d</label>State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), <institution-wrap><institution>Beijing Institute of Lifeomics</institution></institution-wrap>, <city>Beijing</city>, <country>China</country></aff><aff id="aff0005"><label>e</label>Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, <institution-wrap><institution>Shanghai Jiao Tong University School of Medicine</institution></institution-wrap>, <city>Shanghai</city>, <country>China</country></aff><aff id="aff0006"><label>f</label>Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, <institution-wrap><institution>Shanghai Jiao Tong University School of Medicine</institution></institution-wrap>, <city>Shanghai</city>, <country>China</country></aff><aff id="aff0007"><label>g</label>State Key Laboratory of Systems Medicine for Cancer, Institute of Translational Medicine, <institution-wrap><institution>Shanghai Jiao Tong University</institution></institution-wrap>, <city>Shanghai</city>, <country>China</country></aff><aff id="aff0008"><label>h</label>Beijing Tong Ren Hospital, <institution-wrap><institution>Capital Medical University</institution></institution-wrap>, <city>Beijing</city>, <country>China</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Haiyang Liu <email xlink:href="mailto:haiyang_1987@126.com">haiyang_1987@126.com</email> State Key Laboratory of Systems Medicine for Cancer, Institute of Translational Medicine <institution-wrap><institution>Shanghai Jiao Tong University</institution></institution-wrap>, <city>Shanghai</city>, <postal-code>200025</postal-code><country>China</country></corresp><corresp id="an0002">Jianxin Wu <email xlink:href="mailto:jianxinwu_2000@sina.com">jianxinwu_2000@sina.com</email> Beijing Tong Ren Hospital, Capital Medical University, <addr-line>No. 1 Dongjiaominxiang, Dongcheng District</addr-line>, <city>Beijing 100051</city>, <country>China</country></corresp><fn id="an0003"><label>*</label><p>Sen Li and Fangming Kan are co-first authors.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">478705</issue-id><elocation-id seq="26">2548787</elocation-id><pub-history><event event-type="pmc-release"><date><day>29</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>29</day><month>8</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>29</day><month>8</month><year>2025</year></date></event><event event-type="received"><date><day>09</day><month>6</month><year>2025</year></date></event><event event-type="revised"><date><day>11</day><month>8</month><year>2025</year></date></event><event event-type="accepted"><date><day>12</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="KADI_14_2548787.pdf"/><self-uri content-type="pdf" xlink:href="KADI_14_2548787.pdf"/><abstract><title>ABSTRACT</title><p>Obesity lacks physiologically relevant human models, which constrains in-depth investigation into its underlying mechanisms and hampers the development of effective therapeutic strategies for obesity and its associated comorbidities. Here, we developed vascularized adipose organoids (VAOs) from peripheral blood mesenchymal stem cells (PBMSCs) using a standardized three-dimensional dynamic culture system that sequentially induces angiogenesis and adipogenesis. These VAOs mimic native adipose tissue with coexisting adipocytes and endothelial cells. Transcriptomic analysis shows that vascularization alters genes linked to inflammation and redox homoeostasis, yielding distinct metabolic and inflammatory profiles in VAOs versus non-vascularized controls. Notably, upon TNF-&#945; stimulation, VAOs exhibit markedly reduced IL-6&#160;secretion relative to non-vascularized adipose organoids (NVAOs). Importantly, Celastrol simultaneously inhibits angiogenesis and adipogenesis in VAOs and broadly modulates the expression of genes associated with mitochondrial metabolic processes. This study establishes PBMSC-derived VAOs as a scalable, patient-accessible model for investigating adipose development, metabolism, and inflammation. The system also provides a platform for mechanistic research and high-throughput drug screening in obesity and related metabolic diseases.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Obesity</kwd><kwd>Organoid</kwd><kwd>Adipose organoids</kwd><kwd>Vascularized adipose organoids</kwd><kwd>Celastrol</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Beijing Natural Science Foundation</institution></institution-wrap></funding-source><award-id>7234356</award-id></award-group><award-group><funding-source><institution-wrap><institution>Capital Institute of Pediatrics Foundation for Youths</institution></institution-wrap></funding-source><award-id>QN-2024-29</award-id></award-group><award-group><funding-source><institution-wrap><institution>Capital Institute of Pediatrics Scientific and Technological Innovation Achievements Transformation Special Project</institution></institution-wrap></funding-source></award-group><funding-statement>This research was supported by Beijing Natural Science Foundation, grant number [7234356]; Capital Institute of Pediatrics Foundation for Youths, grant number [QN-2024-29]; and Capital Institute of Pediatrics Scientific and Technological Innovation Achievements Transformation Special Project.</funding-statement></funding-group></support-group><counts><fig-count count="4"/><ref-count count="51"/><page-count count="1"/><word-count count="4404"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>Obesity is a pathological condition resulting from abnormal adipose tissue expansion, frequently accompanied by metabolic dysregulation and persistent low-grade inflammation [<xref rid="cit0001" ref-type="bibr">1</xref>]. This chronic low-grade inflammation associated with obesity represents a key mechanistic link between obesity and metabolic complications such as insulin resistance and cardiovascular disease [<xref rid="cit0002" ref-type="bibr">2</xref>]. The absence of physiologically relevant and reproducible human model systems has substantially hindered mechanistic investigations into the pathogenesis of obesity and related metabolic disorders, thereby limiting the development of rational therapeutic strategies with high efficacy and safety [<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0004" ref-type="bibr">4</xref>].</p><p>Adipose organoids are three-dimensional models that closely replicate the structure and function of adipose tissue [<xref rid="cit0005" ref-type="bibr">5</xref>]. Adipose organoids exhibit significantly greater pathophysiological fidelity than conventional two-dimensional cell cultures and animal models by accurately modelling essential characteristics of native adipose tissue, particularly its sophisticated cellular crosstalk between adipocytes, vascular endothelium, and immune populations [<xref rid="cit0006" ref-type="bibr">6&#8211;8</xref>]. Adipose organoids provide a physiologically relevant platform for advancing our understanding of obesity and its complications [<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0009" ref-type="bibr">9</xref>], supporting the development of targeted therapies and enabling high-throughput drug screening for the rapid identification and evaluation of potential therapeutic agents [<xref rid="cit0010" ref-type="bibr">10</xref>].</p><p>Vascularization is essential for accurately modelling adipose tissue and recapitulating its physiological functions, particularly in maintaining metabolic homoeostasis and establishing a functional immune microenvironment [<xref rid="cit0011" ref-type="bibr">11&#8211;13</xref>]. As a critical structural component, the vasculature not only supplies oxygen, nutrients, and bioactive factors that support adipocyte growth, differentiation, and energy metabolism, but also interacts with adipocytes to facilitate tissue repair, regeneration, and the dynamic remodelling of adipose depots [<xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0015" ref-type="bibr">15</xref>]. Some vascularized adipose organoids(VAOs) have already been successfully developed, with current models primarily relying on either the coculture of pluripotent stem cells with endothelial cells and vascular stromal cells, or the incorporation of microvessel fragments to achieve vascularization [<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0016" ref-type="bibr">16&#8211;18</xref>]. While these models represent significant advances in the field, several challenges remain to be addressed, including difficulties in sourcing materials and instability in the consistency between components [<xref rid="cit0019" ref-type="bibr">19</xref>,<xref rid="cit0020" ref-type="bibr">20</xref>].</p><p>In this study, we established a peripheral blood mesenchymal stem cells (PBMSCs) -based VAOs platform employing a standardized three-dimensional dynamic culture system that sequentially induces angiogenesis and adipogenesis. PBMSCs are clinically accessible and can be isolated in a minimally invasive manner from patients and demonstrate robust dual differentiation potential in adipogenesis and angiogenesis [<xref rid="cit0021" ref-type="bibr">21&#8211;24</xref>], which makes them ideal for constructing functional vascularized adipose tissue models. This model successfully generates VAOs containing both adipocytes and vascular endothelial cells effectively recapitulating the multicellular architecture of native adipose tissue. The incorporation of vascular endothelial cells markedly alters the organoid&#8217;s metabolic profile, basal inflammatory state, and response to pro-inflammatory stimuli. Pharmacological evaluation using Celastrol further validated the platform, revealing potent inhibition of adipogenesis and angiogenesis, alongside significant modulation of mitochondrial metabolic processes. The differential response to Celastrol highlights the potential of these PBMSC-derived VAOs, which partially recapitulate adipose tissue biology, as a valuable and physiologically relevant platform for investigating obesity-associated metabolic and inflammatory processes, as well as for therapeutic screening.</p></sec><sec disp-level="1" id="s0002"><title>Results</title><sec disp-level="2" id="s0002-s2001"><title>PBMSC-induced vascularized adipose organoids exhibit both adipocyte and vascular endothelial cell characteristics</title><p>PBMSCs were initially expanded under two-dimensional conditions and then aggregated into three-dimensional spheroids. Sequential induction of angiogenesis and adipogenesis generated VAOs from PBMSC-derived spheroids (<xref rid="f0001" ref-type="fig">Figure 1(A)</xref>); in contrast, Non-vascularized adipose organoids (NVAOs) were established by directly inducing adipogenesis without prior angiogenesis induction. Morphologically, bright-field microscopy revealed branched, vessel-like structures surrounding the VAOs, which were not clearly observed in NVAOs and histological analysis by H&amp;E staining also corroborated the presence of branched, vasculature-like structures in VAOs (<xref rid="f0001" ref-type="fig">Figure 1(B)</xref>). Immunofluorescence staining confirmed the presence of CD31<sup>+</sup> endothelial cells in VAOs, while CD31 expression was minimal in NVAOs (<xref rid="f0001" ref-type="fig">Figure 1(C)</xref>). Oil Red O staining demonstrated the presence of lipid droplets in both organoid types (<xref rid="f0001" ref-type="fig">Figure 1(B)</xref>). Additionally, immunofluorescent staining for the adipocyte-specific marker ASC-1 confirmed the presence of adipocytes in both VAOs and NVAOs (<xref rid="f0001" ref-type="fig">Figure 1(D)</xref>).
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Construction and characterization of VAOs. A. Bright-field images of the generation process of VAOs. B. Bright-field images, H&amp;E staining and Oil Red O staining of VAOs and NVAOs. C. Immunofluorescence detection of the vascular marker CD31 in VAOs and NVAOs. D. Immunofluorescence detection of the adipocyte marker ASC-1 in VAOs and NVAOs. E. VAOs and NVAOs were challenged with TNF-&#945; for 48&#8201;h and IL-6&#160;secretion was quantified by ELISA. (scale bar: 100&#8201;&#181;m; statistical significance: *P&lt;&#8201;0.05, ***&#8201;P&lt;&#8201;0.001).</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0001_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0001_PB.jpg"/></alternatives></fig></p><p>TNF-&#945; can induce inflammatory responses in adipose tissue, one of the primary mechanisms being the promotion of IL-6&#160;secretion [<xref rid="cit0025" ref-type="bibr">25</xref>]. To assess inflammatory responsiveness, both VAOs and NVAOs were exposed to TNF-&#945; (each group with three biological replicates), and IL-6 levels were quantified by ELISA [<xref rid="cit0026" ref-type="bibr">26</xref>] (<xref rid="f0001" ref-type="fig">Figure 1(E)</xref>). In the absence of TNF-&#945;, both organoid types exhibited low basal IL-6&#160;secretion with no significant differences. Upon TNF-&#945; stimulation, both VAOs and NVAOs showed markedly increased IL-6&#160;secretion; however, the increase was significantly higher in NVAOs.</p></sec><sec disp-level="2" id="s0002-s2002"><title>Transcriptomic analysis of vascularized adipose organoids and non-vascularized adipose organoids</title><p>To systematically elucidate the impact of vascularization on adipose organoids, we performed transcriptome profiling using DRUG-seq (each group with three biological replicates) [<xref rid="cit0027" ref-type="bibr">27</xref>]. Principal component analysis (PCA) and hierarchical clustering revealed distinct transcriptomic signatures between VAOs and NVAOs, with high intra-group consistency in VAOs (<xref rid="f0002" ref-type="fig">Figures 2(A,B)</xref>), underscoring the reproducibility of the organoid construction protocol.
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Transcriptomic profiling of VAOs and NVAOs. A. PCA illustrating transcriptome differences between VAOs and NVAOs. B. Hierarchical clustering analysis of DEGs between VAOs and NVAOs. C. GO enrichment analysis of DEGs between VAOs and NVAOs. D. Characterization of DEGs between VAOs and NVAOs (*Padj&#8201;&lt;&#8201;0.05, **Padj&#8201;&lt;&#8201;0.01, ***Padj&#8201;&lt;&#8201;0.001, **** Padj&#8201;&lt;&#8201;0.0001).</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0002_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0002_PB.jpg"/></alternatives></fig></p><p>Differentially expressed genes (DEGs) were identified based on rigorous statistical criteria, with an adjusted p-value (Padj), ensuring the robustness and reliability of the transcriptomic comparisons (Padj&#8201;&lt;&#8201;0.05). Gene Ontology (GO) enrichment analysis of DEGs in VAOs and NVAOs revealed enrichment in processes related to cellular metabolism and inflammatory regulation, including cell redox homoeostasis, Toll-like receptor 4 pathway, response to interferon-beta, IL-27 signalling, and positive regulation of IL-6/IL-8 production [<xref rid="cit0028" ref-type="bibr">28</xref>,<xref rid="cit0029" ref-type="bibr">29</xref>](<xref rid="f0002" ref-type="fig">Figure 2(C)</xref>).</p><p>Comparative DEG analysis (<xref rid="f0002" ref-type="fig">Figure 2(D)</xref>) revealed marked downregulation of FABP4 [<xref rid="cit0030" ref-type="bibr">30</xref>], a key effector of adipocyte function, alongside a modest reduction in the master adipogenesis regulator PPARG [<xref rid="cit0031" ref-type="bibr">31</xref>]. Inflammatory regulatory markers SOCS3 [<xref rid="cit0032" ref-type="bibr">32</xref>] and VCAM1 [<xref rid="cit0033" ref-type="bibr">33</xref>] were upregulated in VAOs. Markers of angiogenesis including PECAM1, ANG, and FGF2 were significantly elevated in VAOs [<xref rid="cit0011" ref-type="bibr">11</xref>], supporting the establishment of vasculature. Additionally, IGF1R [<xref rid="cit0034" ref-type="bibr">34</xref>]-implicated in enhancing insulin sensitivity and maintaining metabolic homoeostasis-was also upregulated.</p></sec><sec disp-level="2" id="s0002-s2003"><title>Celastrol inhibits both adipogenesis and angiogenesis in vascularized adipose organoids</title><p>Celastrol, a natural triterpenoid compound derived from Tripterygium wilfordii, was initially recognized for its role in modulating tumour vascular remodelling in cancer research [<xref rid="cit0035" ref-type="bibr">35</xref>]. In recent years, it has garnered increasing attention for its significant anti-obesity effects and potential to ameliorate metabolic syndrome [<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>]. Animal studies have shown that Celastrol effectively reduces body weight and fat accumulation, primarily through appetite suppression, enhanced energy metabolism, and improved insulin sensitivity [<xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0039" ref-type="bibr">39</xref>]. The dual modulatory effects of Celastrol on both adipocytes and vascular endothelial cells position it as an ideal candidate for assessing the pharmacological responsiveness of our engineered VAO model.</p><p>We investigated the effects of Celastrol (0.5&#8201;&#956;M) by administering it continuously throughout the entire VAOs construction process to assess its impact. Bright-field microscopy observations (<xref rid="f0003" ref-type="fig">Figure 3(A)</xref>) indicated a modest shortening of peripheral vascular-like branching structures in the presence of Celastrol, pointing to a potential anti-angiogenic effect. Histological staining using H&amp;E and Oil Red O (<xref rid="f0003" ref-type="fig">Figure 3(B)</xref>) confirmed that Celastrol inhibited angiogenesis and adipogenesis. To further validate these findings, we performed immunofluorescence staining to detect expression of the vascular marker CD31 and the adipogenic marker ASC-1 in the organoids. The results (<xref rid="f0003" ref-type="fig">Figures 3(C,D)</xref>) reinforced that Celastrol markedly suppressed both angiogenesis and adipogenesis. Moreover, we investigated the effect of Celastrol on the inflammatory response of VAOs upon TNF-&#945; stimulation (each group with three biological replicates), with a particular focus on IL-6&#160;secretion (<xref rid="f0003" ref-type="fig">Figure 3(E)</xref>). The results indicated that Celastrol had little effect on basal IL-6 expression but moderately increased IL-6 levels upon TNF-&#945; stimulation, highlighting its potential immunomodulatory effects in VAOs within an inflammatory context.
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>Effects of Celastrol on VAOs. A. Bright-field images of celastrol-treated (Celastrol<sup>+</sup>) and untreated (Celastrol<sup>&#8722;</sup>) VAOs. B. Bright-field images, H&amp;E and Oil Red O staining of Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. C. Immunofluorescence detection of the vascular marker CD31 in Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. D. Immunofluorescence detection of the adipocyte marker ASC-1 in Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. E. Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs were challenged with TNF-&#945; for 48&#8201;h and IL-6&#160;secretion was quantified by ELISA (scale bar: 100&#8201;&#181;m; *&#8201;P&lt;&#8201;0.05, **&#8201;P&lt;&#8201;0.01).</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0003_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0003_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="s0002-s2004"><title>Transcriptomic analysis of Celastrol&#8217;s effects on vascularized adipose organoids</title><p>To further systematically investigate the biological effects of Celastrol, DRUG-seq was performed to compare Celastrol-treated and untreated VAOs (each group with three biological replicates). PCA and hierarchical clustering confirmed clear separation between the treated and untreated groups (<xref rid="f0004" ref-type="fig">Figures 4(A,B)</xref>).
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Transcriptomic profiling of Celastrol-treated and untreated VAOs. A. PCA illustrating transcriptome differences between Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. B. Hierarchical clustering analysis of DEGs between Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. C. GO enrichment analysis of DEGs between Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. D. Characterization of DEGs between Celastrol<sup>+</sup> and Celastrol<sup>&#8722;</sup> VAOs. (*Padj&#8201;&lt;&#8201;0.05, **Padj&#8201;&lt;&#8201;0.01, ***Padj&#8201;&lt;&#8201;0.001, ****Padj&#8201;&lt;&#8201;0.0001).</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0004_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KADI_A_2548787_F0004_PB.jpg"/></alternatives></fig></p><p>DEGs were identified based on rigorous statistical criteria, with a Padj, ensuring the robustness and reliability of the transcriptomic comparisons (Padj&#8201;&lt;&#8201;0.05). GO enrichment analysis of DEGs revealed significant enrichment in mitochondrial metabolic pathways, including the ubiquinone biosynthetic process, respiratory electron transport chain, mitochondrial electron transport from NADH to ubiquinone, mitochondrial ATP synthesis coupled proton transport, ATP synthesis coupled proton transport, and aerobic respiration (<xref rid="f0004" ref-type="fig">Figure 4(C)</xref>). In addition, significant enrichment of DEGs was observed in pathways related to the angiogenesis-associated Tie signalling pathway, regulation of angiogenesis, and angiogenesis itself. DEGs were also enriched in the positive regulation of the Wnt signalling pathway [<xref rid="cit0031" ref-type="bibr">31</xref>], which is known to suppress adipogenesis by inhibiting the expression of PPARG [<xref rid="cit0031" ref-type="bibr">31</xref>], a key transcription factor required for adipocyte differentiation. Furthermore, enrichment of the ISG15&#8211;protein conjugation pathway suggests that Celastrol may regulate innate immune responses and excessive inflammation through ISG15-mediated modulation of inflammatory signalling [<xref rid="cit0040" ref-type="bibr">40</xref>].</p><p>We also assessed key DEGs related to the processes of related to lipid metabolism, angiogenesis, and inflammation between Celastrol-treated and untreated VAOs (<xref rid="f0004" ref-type="fig">Figure 4(D)</xref>). Regarding lipid metabolism, key lipid droplet formation gene PLIN1 and FABP4 [<xref rid="cit0030" ref-type="bibr">30</xref>] were markedly downregulated. Analysis of inflammation-related genes showed that some key regulatory factors, such as VCAM1 [<xref rid="cit0033" ref-type="bibr">33</xref>] and CCL2, were markedly downregulated, while others, including SOCS3 [<xref rid="cit0032" ref-type="bibr">32</xref>], exhibited only slight reductions in expression. Regarding angiogenesis-related genes, we observed differential regulation patterns: the core angiogenic regulator FGF2 was markedly downregulated, while the vascular stabilization factor TGFB1 showed significant upregulation [<xref rid="cit0015" ref-type="bibr">15</xref>].</p></sec></sec><sec disp-level="1" id="s0003"><title>Discussion</title><p>Vascularization is essential for maintaining the health of adipose tissue, and its role in adipose tissue development and function remains an active area of investigation [<xref rid="cit0041" ref-type="bibr">41</xref>]. On one hand, there is well-established reciprocal crosstalk between endothelial and adipocyte lineages, particularly in promoting adipocyte maturation [<xref rid="cit0005" ref-type="bibr">5</xref>]. On the other hand, whether vascularization promotes or inhibits adipogenesis per se remains controversial [<xref rid="cit0042" ref-type="bibr">42</xref>]. In our results, although PPARG expression exhibited modest variation, the adipocyte marker ASC-1 showed no significant difference between vascularized and non-vascularized conditions. In contrast, comparative transcriptomic profiling revealed widespread alterations in gene expression, with significant enrichment in metabolic and immune-regulatory processes. Previous studies have demonstrated that FABP4 is markedly upregulated under pathological conditions associated with obesity, where it contributes to metabolic dysfunction and chronic inflammation [<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>]. Notably, in our VAO model, we also observed a marked downregulation of FABP4. Functionally, VAOs exhibited markedly attenuated inflammatory responses to TNF-&#945; stimulation, evidenced by a substantial reduction in IL-6&#160;secretion compared to non-vascularized organoids. Together, these findings suggest that while vascularization may not strongly regulate adipogenic commitment in this context, it profoundly modulates the inflammatory and metabolic landscape of adipose organoids, conferring features more closely aligned with metabolically healthy adipose tissue rather than the dysfunctional or immature states [<xref rid="cit0031" ref-type="bibr">31</xref>].</p><p>Celastrol has recently garnered considerable attention for its potent anti-obesity and anti-inflammatory properties [<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>], and has also been reported to exhibit strong anti-angiogenic activity, particularly in the context of tumour progression [<xref rid="cit0035" ref-type="bibr">35</xref>]. Consistent with these properties, our experimental results demonstrate that Celastrol significantly inhibits both adipogenesis and angiogenesis in VAOs. Transcriptomic profiling further revealed that Celastrol profoundly alters key biological processes related to adipogenesis and angiogenesis, while significantly modulating mitochondrial metabolic pathways and inflammatory responses; notably, these changes are also highly consistent with findings reported in previous studies [<xref rid="cit0044" ref-type="bibr">44&#8211;46</xref>]. Notably, Celastrol suppressed the key angiogenic factor FGF2 [<xref rid="cit0047" ref-type="bibr">47</xref>]&#8212;while upregulating TGF-&#946;1 [<xref rid="cit0048" ref-type="bibr">48</xref>], suggesting that Celastrol may suppress angiogenesis by promoting endothelial apoptosis.</p><p>In healthy adipose tissue, coordinated angiogenesis and adipogenesis are essential for metabolic homoeostasis [<xref rid="cit0031" ref-type="bibr">31</xref>]. While Celastrol potently inhibits both processes, offering potential therapeutic value for obesity, excessive suppression may disrupt adipose integrity and function, underscoring the need for careful evaluation of its metabolic consequences. Notably, our study found that Celastrol markedly suppressed the pro-inflammatory factor FABP4, yet more strikingly downregulated PLIN1. This downregulation of FABP4 and PLIN1 upon Celastrol treatment has also been reported by other researchers [<xref rid="cit0049" ref-type="bibr">49</xref>]. Based on FABP4 alone, this downregulation suggests that Celastrol may indeed help restore a healthier metabolic phenotype in adipose tissue. PLIN1 is a key regulator of lipid droplet stability and adipocyte lipolysis, as well as a critical marker and functional regulator of healthy adipose tissue, whose reduction may lead to adipocyte dysfunction, increased lipotoxicity, and heightened risk of metabolic diseases [<xref rid="cit0050" ref-type="bibr">50</xref>]. In addition, PLIN1-expressing adipocyte subpopulations are associated not only with enhanced insulin sensitivity but also with proper lipid droplet stability and regulated lipolysis, and these subpopulations are diminished in obesity [<xref rid="cit0051" ref-type="bibr">51</xref>]. Taken together, the downregulation of PLIN1 raises concerns regarding potential lipotoxicity, impaired adipocyte function, and increased metabolic risk. Additionally, we also found that Celastrol increased IL-6&#160;secretion upon TNF-&#945; stimulation in our study. Together, these findings underscore the need for cautious interpretation of Celastrol&#8217;s therapeutic potential in obesity treatment.</p><p>In summary, we successfully established a VAOs model from PBMSCs that recapitulates key cellular features of native adipose tissue, including the coexistence of adipocytes and endothelial cells. The induction protocol was streamlined and highly reproducible. Compared to NVAOs, VAOs exhibited improved metabolic and inflammatory profiles, including a notably reduced response to external inflammatory stimuli, offering a model exhibiting relevance for the study of obesity-related mechanisms. In addition, their distinct transcriptional and phenotypic response to Celastrol &#8211; marked by concurrent suppression of angiogenic and adipogenic programmes &#8211; underscores the potential of VAOs as a physiologically relevant platform for studying obesity-related mechanisms and therapeutic screening.</p></sec><sec disp-level="1" id="s0004"><title>Materials and methods</title><sec disp-level="2" id="s0004-s2001"><title>Materials</title><p>The culture medias used in this study were as follows. Medium S1 consisted of DMEM/F12 supplemented with 15% FBS and 500X Primocin. Medium S2 consisted of 95% EBM-2, 5% FBS, 100&#8201;ng/ml VEGF, 50&#8201;ng/ml EGF, 100&#8201;ng/ml bFGF, 1&#8201;&#181;g/ml ascorbic acid, 0.2&#8201;&#181;g/ml hydrocortisone, 30&#8201;&#181;g/ml gentamicin, 15&#8201;ng/ml amphotericin, 100&#8201;ng/ml LR3-IGF-1, and 500X primocin. Medium S3 included 84% DMEM/F12, 2.5% FBS, 0.2&#8201;&#181;M insulin, 0.5&#8201;mM 3-isobutyl-1-methylxanthine (IBMX), 0.25&#8201;&#181;M dexamethasone, 1% GlutaMAX, 10&#8201;&#181;g/ml transferrin, and 500X primocin, with the remaining volume supplemented with DMEM/F12. Finally, Medium S4 contained 87% DMEM/F12, 12% FBS, 5&#8201;&#181;g/ml insulin, 1% GlutaMAX, and 500X primocin; Medium S5 contained 89% DMEM/F12, 10% FBS, 1% GlutaMAX, and 500X primocin.</p></sec><sec disp-level="2" id="s0004-s2002"><title>Cell culture</title><p>PBMSCs (HUM-iCell-i016, iCell) were cultured in T75 flasks in high-glucose DMEM/F12 medium supplemented with 10% FBS. Cells were digested with 0.25% trypsin and used to form mesenchymal stem cell organoids after two passages.</p></sec><sec disp-level="2" id="s0004-s2003"><title>Induction of three-dimensional adipose organoids</title><p>PBMSCs were cultured in S1 medium and cells were digested with 0.25% trypsin. Then, the cell suspension was centrifuged at 300&#8201;&#215;&#8201;g for 5&#8201;min to collect cells. Then, the harvested cells were resuspended in S1 culture medium, and the cell density was adjusted to 1&#8201;&#215;&#8201;10^4 cells per well. One hundred microlitres of the suspension was inoculated into each well of a 96-well ultralow adsorption plate. The plate was placed in an incubator at 37&#176;C with 5% CO<sub>2</sub> for 2&#8211;3&#8201;days to promote the formation of cell aggregates.</p><p>The cell aggregates (spheroids) were subsequently subjected to adipogenic induction in S3 medium for 3&#8201;days followed by an additional 10&#8211;12&#8201;days of induction with S4 medium to promote adipocyte formation. Organoids were then cultured in S5 medium for 6&#8201;days to obtain mature organoids. These mature organoids were used for fixation and staining, TNF-&#945; stimulation, and transcriptome sequencing.</p></sec><sec disp-level="2" id="s0004-s2004"><title>Induction of three-dimensional vascularized adipose organoids</title><p>PBMSCs were cultured in S1 medium. The cells were digested with 0.25% trypsin and the cell suspension was centrifuged at 300&#8201;&#215;&#8201;g for 5&#8201;min to collect cells. Harvested cells were resuspended in S1 culture medium, and the cell density was adjusted to 1&#8201;&#215;&#8201;10^4 cells per well. One hundred microlitres of this suspension was inoculated into each well of a 96-well ultralow adsorption plate. The plate was placed in an incubator at 37&#176;C with 5% CO<sub>2</sub> for 2&#8211;3&#8201;days to facilitate the formation of cell aggregates.</p><p>500&#956;L of S2 medium was added to each well of a 24-well ultralow adsorption plate, and 3&#8211;4 cell spheres were transferred to each well. The mixture was incubated at 37&#176;C with 5% CO<sub>2</sub> for 4&#8201;days, and the medium was changed every 2&#8211;3&#8201;days.</p><p>A groove in the sealing foil was prepared, and a ball of cells was transferred into the concave hole of the sealing foil using a wide-mouth pipette tip. The excess culture medium was removed, and one well was added together with 10&#8201;&#956;L of Matrigel (Corning 254234). Then, the spheroids were left in the incubator until the Matrigel solidified. Then, the droplets were washed into an ultralow adsorption six-well plate with S2 culture medium and the suspension culture was continued. Suspension induction in S2 culture medium takes 4 to 5&#8201;days to produce organoids with vascular structures, and the medium is changed once every 2 to 3&#8201;days. Organoids were subjected to adipogenesis-directed induction for 3&#8201;days in S3 medium. The medium was then replaced with S4 medium to continue the adipogenic induction of the organoids for 10&#8211;12&#8201;days, which resulted in vascularized adipose organoids with mature adipocytes over 40&#8201;&#956;m in diameter. Finally, organoids were cultured in S5 medium for 6&#8201;days to obtain vascularized adipose organoids containing vascular endothelial cells and mature adipocytes, which were then used for fixed staining, TNF-&#945; stimulation, and transcriptome sequencing.</p></sec><sec disp-level="2" id="s0004-s2005"><title>Drug intervention in the induction of three-dimensional vascularized adipose organoids</title><p>In this study, Celastrol was used to intervene in the induction of three-dimensional vascularized adipose organoids. Specifically, the drug (selleck, Cat. No. S1290) was incorporated into the culture medias S1-S5 at a final concentration of 0.5&#8201;&#181;M, which served as the drug intervention medium. Following the established steps for the induction of vascularized adipose organoids, drug-enriched culture medium was used to induce organoids, while those induced with drug-free culture medium were designated as the control group.</p></sec><sec disp-level="2" id="s0004-s2006"><title>Histochemical staining</title><p>Three-dimensional constructs were fixed overnight in 10% neutral buffered formalin (NBF) at 4&#176;C. Fixed organoids were then processed for paraffin embedding and sectioning. Slides were deparaffinised and rehydrated in water before being stained with Harris haematoxylin and eosin to visualize their morphology.</p><p>For Oil Red O staining, frozen sections were used, frozen sections were fixed with 10% neutral formalin for 30&#8201;minutes at room temperature, followed by incubation with 60% isopropanol in water for 5&#8201;minutes. The samples were then incubated with Oil Red O for 15&#8201;minutes. After thorough rinsing with 60% isopropyl alcohol in water, imaging was performed to visualize the lipid composition of the three-dimensional cultures.</p></sec><sec disp-level="2" id="s0004-s2007"><title>Immunofluorescence staining</title><p>For immunofluorescence staining, frozen sections were used, frozen sections of organoids were prepared, and CD31 and ASC-1 were used for identification. Specifically, CD31 (Abcam; ab28364) was used to identify vascular endothelial cell, whereas ASC-1 (Affinity; DF9230) was used to identify adipocyte.</p></sec><sec disp-level="2" id="s0004-s2008"><title>Tumour necrosis factor alpha (TNF-alpha) stimulation</title><p>Organoids were inoculated and cultured as described above. After organoids matured, 200&#8201;&#181;L of the organoid culture supernatant was collected as a prestimulation sample of TNF-&#945; (R&amp;D Systems, Cat. 210-TA-020). Subsequently, TNF-&#945; was added at a final concentration of 50&#8201;ng/mL in medium (Cat. No. 210-TA-020; Brand: R&amp;D) and incubated for 48&#8201;hours. Then, the supernatant was collected as a sample after TNF-&#945; stimulation. An ELISA detection kit (Cat. No. EK0410, Brand: Boster) was used to measure IL-6&#160;secretion. Each set of samples contained three replicates.</p></sec><sec disp-level="2" id="s0004-s2009"><title>Interleukin-6 (IL-6) enzyme-linked immunosorbent assay (ELISA)</title><p>The supernatant from organoids treated with or without tumour necrosis factor-&#945; (TNF-&#945;) was transferred to a microcentrifuge tube. Samples were then diluted and centrifuged at 12,000 rpm for 2&#8201;minutes. Following the manufacturer&#8217;s instructions, the supernatant was analysed using an enzyme-linked immunosorbent assay (ELISA) to quantify secreted interleukin-6.</p></sec><sec disp-level="2" id="s0004-s2010"><title>Total RNA extraction of samples</title><p>The RNA extraction from organoids was performed following the manufacturer&#8217;s protocol on Isolation of RNA from organoids and spheroids (TFS-Assets/BID/Reference-Materials/isolation-rna-organoids-spheroids-white-paper.pdf).</p></sec><sec disp-level="2" id="s0004-s2011"><title>Poly(A) RNA capture</title><p>Total RNA (100 ng) was added to the drug beads and 2x binding buffer and then mixed and incubated at room temperature for 15&#8201;minutes. The supernatant was removed by magnetic separation.</p></sec><sec disp-level="2" id="s0004-s2012"><title>Library preparation</title><p>DTT, dNTPs, RNase Inhibitor, RT Enzyme and 5x RT Buffer were added to the previous product to synthesize single-stranded cDNA. The supernatant was removed by magnetic separation, and single-stranded DNA was removed by adding Exonuclease I and 10x Exonuclease I Buffer. Then, the supernatant was removed by magnetic separation, and the Poly(A) RNA was removed through the addition of elution buffer. Random primers, 10x reaction buffer, enhancers, dNTPs and cDNA Extend Polymerase I were used for two-strand cDNA synthesis. After the supernatant was removed the elution buffer was added. DNA beads were then added to the supernatant to recover fragments. Finally, the 2x HIFI Amplification Mix and Index were added, and PCR amplification of the library fragments was performed. Then, the library fragments of the DNA beads were examined.</p></sec><sec disp-level="2" id="s0004-s2013"><title>Sequencing</title><p>A Bioptic Qsep100 Analyzer was used for the library quality control to check that the library size distribution matched the theoretical size. The NovaSeq high-throughput sequencing platform and PE150 sequencing mode were used for sequencing.</p></sec><sec disp-level="2" id="s0004-s2014"><title>Data analysis</title><p>DRUG-seq was performed by Guangzhou Epibiotek Co., Ltd. on an Illumina NovaSeq 6000 platform (Illumina, San Diego, CA, USA). Raw reads were filtered to remove adaptors via Cutadapt (v2.5; <ext-link xlink:href="https://cutadapt.readthedocs.io/en/stable/" ext-link-type="uri">https://cutadapt.readthedocs.io/en/stable/</ext-link>). The sequenced reads were single-end mapped to reference genome sequences (human GRCh38) via the Next Gen Map (v0.5.5; <ext-link xlink:href="http://cibiv.github.io/NextGenMap/" ext-link-type="uri">http://cibiv.github.io/NextGenMap/</ext-link>) and SAM tools (v1.10; <ext-link xlink:href="http://samtools.sourceforge.net" ext-link-type="uri">http://samtools.sourceforge.net</ext-link>), and feature counts (v1.6.3; <ext-link xlink:href="https://subread.sourceforge.net/featureCounts.html" ext-link-type="uri">https://subread.sourceforge.net/featureCounts.html</ext-link>) were used to quantify the mapped sequences. A differential expression analysis was performed using DESeq2 (v1.18.1). Padj for multiple testing, using Benjamini-Hochberg to estimate the false discovery rate (FDR), were calculated for final estimation of differential expression significance(Padj&#8201;&lt;&#8201;0.05). PCA, hierarchical clustering, and GO enrichment analyses were performed via the R package.</p></sec><sec disp-level="2" id="s0004-s2015"><title>Statistical analysis</title><p>The IL-6&#160;secretion data from the TNF-&#945; stimulation experiments were statistically analysed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). For comparisons between two groups, an unpaired Student&#8217;s t-test was applied. A significance level of &#8201;P&lt;&#8201;0.05 was considered for all analyses.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank Kingbio Medical (Chongqing, China) Co., Ltd. for providing services and assistance with organoid experiments.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0005"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="s0006"><title>Data availability statement</title><p>The data presented in this study are openly available in Gene Expression Omnibus (GEO) at <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289261" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289261</ext-link>, reference number GSE289261.</p></sec><sec disp-level="1" id="s0007"><title>Institutional review board statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Capital Institute of Pediatrics (protocol code SHERLLM2023051).</p></sec><ref-list><title>References</title><ref id="cit0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pereira</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Alvarez-Leite</surname><given-names>JI.</given-names></string-name></person-group><article-title>Low-grade inflammation, obesity, and diabetes</article-title>. <source>Curr Obes Rep</source>. <year>2014</year>;<volume>3</volume>(<issue>4</issue>):<fpage>422</fpage>&#8211;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13679-014-0124-9</pub-id><pub-id pub-id-type="pmid">26626919</pub-id></mixed-citation></ref><ref id="cit0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rohm</surname><given-names>TV</given-names></string-name>, <string-name name-style="western"><surname>Meier</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Olefsky</surname><given-names>JM</given-names></string-name>, et al</person-group>. <article-title>Inflammation in obesity, diabetes, and related disorders</article-title>. <source>Immunity</source>. <year>2022</year>;<volume>55</volume>(<issue>1</issue>):<fpage>31</fpage>&#8211;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2021.12.013</pub-id><pub-id pub-id-type="pmid">35021057</pub-id><pub-id pub-id-type="pmcid">PMC8773457</pub-id></mixed-citation></ref><ref id="cit0003"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kleinert</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Clemmensen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hofmann</surname><given-names>SM</given-names></string-name>, et al</person-group>. <article-title>Animal models of obesity and diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. <year>2018</year>;<volume>14</volume>(<issue>3</issue>):<fpage>140</fpage>&#8211;<lpage>162</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrendo.2017.161</pub-id><pub-id pub-id-type="pmid">29348476</pub-id></mixed-citation></ref><ref id="cit0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruiz-Ojeda</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Ruperez</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Gomez-Llorente</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Cell models and their application for studying adipogenic differentiation in relation to obesity: a review</article-title>. <source>Int J Mol Sci</source>. <year>2016</year>;<volume>17</volume>(<issue>7</issue>):<fpage>1040</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms17071040</pub-id><pub-id pub-id-type="pmid">27376273</pub-id><pub-id pub-id-type="pmcid">PMC4964416</pub-id></mixed-citation></ref><ref id="cit0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Unleashing the potential of adipose organoids: a revolutionary approach to combat obesity-related metabolic diseases</article-title>. <source>Theranostics</source>. <year>2024</year>;<volume>14</volume>(<issue>5</issue>):<fpage>2075</fpage>&#8211;<lpage>2098</lpage>. doi: <pub-id pub-id-type="doi">10.7150/thno.93919</pub-id><pub-id pub-id-type="pmid">38505622</pub-id><pub-id pub-id-type="pmcid">PMC10945346</pub-id></mixed-citation></ref><ref id="cit0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>JR</given-names></string-name>, et al</person-group>. <article-title>Short-term spheroid formation enhances the regenerative capacity of adipose-derived stem cells by promoting stemness, angiogenesis, and chemotaxis</article-title>. <source>Stem Cells Transl Med</source>. <year>2013</year>;<volume>2</volume>(<issue>8</issue>):<fpage>584</fpage>&#8211;<lpage>594</lpage>. doi: <pub-id pub-id-type="doi">10.5966/sctm.2013-0007</pub-id><pub-id pub-id-type="pmid">23847001</pub-id><pub-id pub-id-type="pmcid">PMC3726138</pub-id></mixed-citation></ref><ref id="cit0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Okumus</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Boke</surname><given-names>OB</given-names></string-name>, <string-name name-style="western"><surname>Turhan</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Dogan</surname><given-names>A</given-names></string-name></person-group>. <article-title>From development to future prospects: the adipose tissue &amp; adipose tissue organoids</article-title>. <source>Life Sci</source>. <year>2024</year>;<volume>351</volume>:<fpage>122758</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2024.122758</pub-id><pub-id pub-id-type="pmid">38823504</pub-id></mixed-citation></ref><ref id="cit0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sellin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kuerschner</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Generation of immune cell containing adipose organoids for in vitro analysis of immune metabolism</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>21104</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-78015-9</pub-id><pub-id pub-id-type="pmid">33273595</pub-id><pub-id pub-id-type="pmcid">PMC7713299</pub-id></mixed-citation></ref><ref id="cit0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turner</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>SJ</given-names></string-name>, et al</person-group>. <article-title>Three-dimensional spheroid cell model of in vitro adipocyte inflammation</article-title>. <source>Tissue Eng Part A</source>. <year>2015</year>;<volume>21</volume>(<issue>11&#8211;12</issue>):<fpage>1837</fpage>&#8211;<lpage>1847</lpage>. doi: <pub-id pub-id-type="doi">10.1089/ten.tea.2014.0531</pub-id><pub-id pub-id-type="pmid">25781458</pub-id></mixed-citation></ref><ref id="cit0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lazar</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Modelling metabolic diseases and drug response using stem cells and organoids</article-title>. <source>Nat Rev Endocrinol</source>. <year>2022</year>;<volume>18</volume>(<issue>12</issue>):<fpage>744</fpage>&#8211;<lpage>759</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41574-022-00733-z</pub-id><pub-id pub-id-type="pmid">36071283</pub-id><pub-id pub-id-type="pmcid">PMC9449917</pub-id></mixed-citation></ref><ref id="cit0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ioannidou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Hagberg</surname><given-names>CE</given-names></string-name></person-group>. <article-title>The multifaceted roles of the adipose tissue vasculature</article-title>. <source>Obes Rev</source>. <year>2022</year>;<volume>23</volume>(<issue>4</issue>):<fpage>e13403</fpage>. doi: <pub-id pub-id-type="doi">10.1111/obr.13403</pub-id><pub-id pub-id-type="pmid">34866318</pub-id></mixed-citation></ref><ref id="cit0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Escudero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vaysse</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Eke</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Scalable generation of pre-vascularized and functional human beige adipose organoids</article-title>. <source>Adv Sci (Weinh)</source>. <year>2023</year>;<volume>10</volume>(<issue>31</issue>):<fpage>e2301499</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202301499</pub-id><pub-id pub-id-type="pmid">37731092</pub-id><pub-id pub-id-type="pmcid">PMC10625054</pub-id></mixed-citation></ref><ref id="cit0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>AlZaim</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>de Rooij</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sheikh</surname><given-names>BN</given-names></string-name>, et al</person-group>. <article-title>The evolving functions of the vasculature in regulating adipose tissue biology in health and obesity</article-title>. <source>Nat Rev Endocrinol</source>. <year>2023</year>;<volume>19</volume>(<issue>12</issue>):<fpage>691</fpage>&#8211;<lpage>707</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41574-023-00893-6</pub-id><pub-id pub-id-type="pmid">37749386</pub-id></mixed-citation></ref><ref id="cit0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Augustin</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Koh</surname><given-names>GY</given-names></string-name></person-group>. <article-title>Organotypic vasculature: from descriptive heterogeneity to functional pathophysiology</article-title>. <source>Science</source>. <year>2017</year>;<volume>357</volume>(<issue>6353</issue>). doi: <pub-id pub-id-type="doi">10.1126/science.aal2379</pub-id><pub-id pub-id-type="pmid">28775214</pub-id></mixed-citation></ref><ref id="cit0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Strobel</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Moss</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Hoying</surname><given-names>JB</given-names></string-name></person-group>. <article-title>Vascularized tissue organoids</article-title>. <source>Bioengineering (Basel)</source>. <year>2023</year>;<volume>10</volume>(<issue>2</issue>):<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.3390/bioengineering10020124</pub-id><pub-id pub-id-type="pmcid">PMC9951914</pub-id><pub-id pub-id-type="pmid">36829618</pub-id></mixed-citation></ref><ref id="cit0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Strobel</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Gerton</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hoying</surname><given-names>JB</given-names></string-name></person-group>. <article-title>Vascularized adipocyte organoid model using isolated human microvessel fragments</article-title>. <source>Biofabrication</source>. <year>2021</year>;<volume>13</volume>(<issue>3</issue>):<fpage>035022</fpage>. doi: <pub-id pub-id-type="doi">10.1088/1758-5090/abe187</pub-id><pub-id pub-id-type="pmid">33513595</pub-id></mixed-citation></ref><ref id="cit0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Muller</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ader</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Creff</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Human adipose stromal-vascular fraction self-organizes to form vascularized adipose tissue in 3D cultures</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>7250</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-43624-6</pub-id><pub-id pub-id-type="pmid">31076601</pub-id><pub-id pub-id-type="pmcid">PMC6510792</pub-id></mixed-citation></ref><ref id="cit0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Purified adipose tissue-derived extracellular vesicles facilitate adipose organoid vascularization through coordinating adipogenesis and angiogenesis</article-title>. <source>Biofabrication</source>. <year>2025</year>;<volume>17</volume>(<issue>2</issue>):<fpage>17</fpage>. doi: <pub-id pub-id-type="doi">10.1088/1758-5090/adb2e7</pub-id><pub-id pub-id-type="pmid">39908669</pub-id></mixed-citation></ref><ref id="cit0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dowbaj</surname><given-names>AM</given-names></string-name>, et al</person-group>. <article-title>Organoids</article-title>. <source>Nat Rev Methods Primers</source>. <year>2022</year>;<volume>2</volume>(<issue>1</issue>). doi: <pub-id pub-id-type="doi">10.1038/s43586-022-00174-y</pub-id><pub-id pub-id-type="pmcid">PMC10270325</pub-id><pub-id pub-id-type="pmid">37325195</pub-id></mixed-citation></ref><ref id="cit0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hofer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lutolf</surname><given-names>MP</given-names></string-name></person-group>. <article-title>Engineering organoids</article-title>. <source>Nat Rev Mater</source>. <year>2021</year>;<volume>6</volume>(<issue>5</issue>):<fpage>402</fpage>&#8211;<lpage>420</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41578-021-00279-y</pub-id><pub-id pub-id-type="pmid">33623712</pub-id><pub-id pub-id-type="pmcid">PMC7893133</pub-id></mixed-citation></ref><ref id="cit0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name></person-group>. <article-title>Concise review: multipotent mesenchymal stromal cells in blood</article-title>. <source>Stem Cells</source>. <year>2007</year>;<volume>25</volume>(<issue>1</issue>):<fpage>69</fpage>&#8211;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1634/stemcells.2006-0335</pub-id><pub-id pub-id-type="pmid">16973831</pub-id></mixed-citation></ref><ref id="cit0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>JC</given-names></string-name>, et al</person-group>. <article-title>Peripheral blood-derived mesenchymal stem cells: candidate cells responsible for healing critical-sized calvarial bone defects</article-title>. <source>Stem Cells Transl Med</source>. <year>2015</year>;<volume>4</volume>(<issue>4</issue>):<fpage>359</fpage>&#8211;<lpage>368</lpage>. doi: <pub-id pub-id-type="doi">10.5966/sctm.2014-0150</pub-id><pub-id pub-id-type="pmid">25742693</pub-id><pub-id pub-id-type="pmcid">PMC4367504</pub-id></mixed-citation></ref><ref id="cit0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Beta-Catenin promotes long-term survival and angiogenesis of peripheral blood mesenchymal stem cells via the Oct4 signaling pathway</article-title>. <source>Exp Mol Med</source>. <year>2022</year>;<volume>54</volume>(<issue>9</issue>):<fpage>1434</fpage>&#8211;<lpage>1449</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s12276-022-00839-4</pub-id><pub-id pub-id-type="pmid">36050404</pub-id><pub-id pub-id-type="pmcid">PMC9535028</pub-id></mixed-citation></ref><ref id="cit0024"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Osteogenesis of peripheral blood mesenchymal stem cells in self assembling peptide nanofiber for healing critical size calvarial bony defect</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>(<issue>1</issue>):<fpage>16681</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep16681</pub-id><pub-id pub-id-type="pmid">26568114</pub-id><pub-id pub-id-type="pmcid">PMC4645224</pub-id></mixed-citation></ref><ref id="cit0025"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gregor</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Hotamisligil</surname><given-names>GS</given-names></string-name></person-group>. <article-title>Inflammatory mechanisms in obesity</article-title>. <source>Annu Rev Immunol</source>. <year>2011</year>;<volume>29</volume>(<issue>1</issue>):<fpage>415</fpage>&#8211;<lpage>445</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101322</pub-id><pub-id pub-id-type="pmid">21219177</pub-id></mixed-citation></ref><ref id="cit0026"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abbott</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>RY</given-names></string-name>, <string-name name-style="western"><surname>Reagan</surname><given-names>MR</given-names></string-name>, et al</person-group>. <article-title>The use of silk as a scaffold for mature, sustainable unilocular adipose 3D tissue engineered systems</article-title>. <source>Adv Healthc Mater</source>. <year>2016</year>;<volume>5</volume>(<issue>13</issue>):<fpage>1667</fpage>&#8211;<lpage>1677</lpage>. doi: <pub-id pub-id-type="doi">10.1002/adhm.201600211</pub-id><pub-id pub-id-type="pmid">27197588</pub-id><pub-id pub-id-type="pmcid">PMC4982640</pub-id></mixed-citation></ref><ref id="cit0027"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ye</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Neri</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>4307</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-018-06500-x</pub-id><pub-id pub-id-type="pmid">30333485</pub-id><pub-id pub-id-type="pmcid">PMC6192987</pub-id></mixed-citation></ref><ref id="cit0028"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>IL-27 alleviates high-fat diet-induced obesity and metabolic disorders by inhibiting adipogenesis via activating HDAC6</article-title>. <source>Commun Biol</source>. <year>2025</year>;<volume>8</volume>(<issue>1</issue>):<fpage>460</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s42003-025-07918-y</pub-id><pub-id pub-id-type="pmid">40108289</pub-id><pub-id pub-id-type="pmcid">PMC11923273</pub-id></mixed-citation></ref><ref id="cit0029"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vilotic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nacka-Aleksic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pirkovic</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>IL-6 and IL-8: an overview of their roles in healthy and pathological pregnancies</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>23</issue>):<fpage>23</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms232314574</pub-id><pub-id pub-id-type="pmcid">PMC9738067</pub-id><pub-id pub-id-type="pmid">36498901</pub-id></mixed-citation></ref><ref id="cit0030"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Furuhashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saitoh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shimamoto</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases</article-title>. <source>Clin Med Insights Cardiol</source>. <year>2014</year>;<volume>8</volume>:<fpage>23</fpage>&#8211;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.4137/CMC.S17067</pub-id><pub-id pub-id-type="pmcid">PMC4315049</pub-id><pub-id pub-id-type="pmid">25674026</pub-id></mixed-citation></ref><ref id="cit0031"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghaben</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Scherer</surname><given-names>PE</given-names></string-name></person-group>. <article-title>Adipogenesis and metabolic health</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2019</year>;<volume>20</volume>(<issue>4</issue>):<fpage>242</fpage>&#8211;<lpage>258</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41580-018-0093-z</pub-id><pub-id pub-id-type="pmid">30610207</pub-id></mixed-citation></ref><ref id="cit0032"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carow</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rottenberg</surname><given-names>ME</given-names></string-name></person-group>. <article-title>SOCS3, a major regulator of infection and inflammation</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>:<fpage>58</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2014.00058</pub-id><pub-id pub-id-type="pmid">24600449</pub-id><pub-id pub-id-type="pmcid">PMC3928676</pub-id></mixed-citation></ref><ref id="cit0033"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumari</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>ICAM-1 and VCAM-1: gatekeepers in various inflammatory and cardiovascular disorders</article-title>. <source>Clin Chim Acta</source>. <year>2023</year>;<volume>548</volume>:<fpage>117487</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cca.2023.117487</pub-id><pub-id pub-id-type="pmid">37442359</pub-id></mixed-citation></ref><ref id="cit0034"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boucher</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Softic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>El Ouaamari</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Differential roles of insulin and IGF-1 receptors in adipose tissue development and function</article-title>. <source>Diabetes</source>. <year>2016</year>;<volume>65</volume>(<issue>8</issue>):<fpage>2201</fpage>&#8211;<lpage>2213</lpage>. doi: <pub-id pub-id-type="doi">10.2337/db16-0212</pub-id><pub-id pub-id-type="pmid">27207537</pub-id><pub-id pub-id-type="pmcid">PMC4955980</pub-id></mixed-citation></ref><ref id="cit0035"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tan</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>XY</given-names></string-name>, et al</person-group>. <article-title>Celastrol: the new dawn in the treatment of vascular remodeling diseases</article-title>. <source>Biomed Pharmacother</source>. <year>2023</year>;<volume>158</volume>:<fpage>114177</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2022.114177</pub-id><pub-id pub-id-type="pmid">36809293</pub-id></mixed-citation></ref><ref id="cit0036"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Salazar Hernandez</surname><given-names>MA</given-names></string-name>, et al</person-group>. <article-title>Treatment of obesity with celastrol</article-title>. <source>Cell</source>. <year>2015</year>;<volume>161</volume>(<issue>5</issue>):<fpage>999</fpage>&#8211;<lpage>1011</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2015.05.011</pub-id><pub-id pub-id-type="pmid">26000480</pub-id><pub-id pub-id-type="pmcid">PMC4768733</pub-id></mixed-citation></ref><ref id="cit0037"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Greenhill</surname><given-names>C</given-names></string-name></person-group>. <article-title>Celastrol identified as a leptin sensitizer and potential novel treatment for obesity</article-title>. <source>Nat Rev Endocrinol</source>. <year>2015</year>;<volume>11</volume>(<issue>8</issue>):<fpage>444</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrendo.2015.94</pub-id><pub-id pub-id-type="pmid">26055047</pub-id></mixed-citation></ref><ref id="cit0038"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Celastrol prevents high-fat diet-induced obesity by promoting white adipose tissue browning</article-title>. <source>Clin Transl Med</source>. <year>2021</year>;<volume>11</volume>(<issue>12</issue>):<fpage>e641</fpage>. doi: <pub-id pub-id-type="doi">10.1002/ctm2.641</pub-id><pub-id pub-id-type="pmid">34911164</pub-id><pub-id pub-id-type="pmcid">PMC8673360</pub-id></mixed-citation></ref><ref id="cit0039"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Alberobello</surname><given-names>AT</given-names></string-name>, et al</person-group>. <article-title>Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1alpha transcriptional axis</article-title>. <source>Cell Metab</source>. <year>2015</year>;<volume>22</volume>(<issue>4</issue>):<fpage>695</fpage>&#8211;<lpage>708</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2015.08.005</pub-id><pub-id pub-id-type="pmid">26344102</pub-id></mixed-citation></ref><ref id="cit0040"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kang</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>YJ</given-names></string-name></person-group>. <article-title>The diverse repertoire of ISG15: more intricate than initially thought</article-title>. <source>Exp Mol Med</source>. <year>2022</year>;<volume>54</volume>(<issue>11</issue>):<fpage>1779</fpage>&#8211;<lpage>1792</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s12276-022-00872-3</pub-id><pub-id pub-id-type="pmid">36319753</pub-id><pub-id pub-id-type="pmcid">PMC9722776</pub-id></mixed-citation></ref><ref id="cit0041"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harvey</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Boudreau</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jmjob</surname><given-names>S</given-names></string-name></person-group>. <article-title>Adipose tissue in health and disease</article-title>. <source>Open Biol</source>. <year>2020</year>;<volume>10</volume>(<issue>12</issue>):<fpage>200291</fpage>. doi: <pub-id pub-id-type="doi">10.1098/rsob.200291</pub-id><pub-id pub-id-type="pmid">33292104</pub-id><pub-id pub-id-type="pmcid">PMC7776562</pub-id></mixed-citation></ref><ref id="cit0042"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baganha</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Schipper</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hagberg</surname><given-names>CE</given-names></string-name></person-group>. <article-title>Towards better models for studying human adipocytes in vitro</article-title>. <source>Adipocyte</source>. <year>2022</year>;<volume>11</volume>(<issue>1</issue>):<fpage>413</fpage>&#8211;<lpage>419</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21623945.2022.2104514</pub-id><pub-id pub-id-type="pmid">35894386</pub-id><pub-id pub-id-type="pmcid">PMC9331194</pub-id></mixed-citation></ref><ref id="cit0043"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Z</given-names></string-name>, et al</person-group>. <article-title>FABP4 in obesity-associated carcinogenesis: novel insights into mechanisms and therapeutic implications</article-title>. <source>Front Mol Biosci</source>. <year>2022</year>;<volume>9</volume>:<fpage>973955</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmolb.2022.973955</pub-id><pub-id pub-id-type="pmid">36060264</pub-id><pub-id pub-id-type="pmcid">PMC9438896</pub-id></mixed-citation></ref><ref id="cit0044"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells</article-title>. <source>BMC Cancer</source>. <year>2011</year>;<volume>11</volume>(<issue>1</issue>):<fpage>170</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2407-11-170</pub-id><pub-id pub-id-type="pmid">21569548</pub-id><pub-id pub-id-type="pmcid">PMC3112161</pub-id></mixed-citation></ref><ref id="cit0045"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of beta-catenin</article-title>. <source>Acta Pharmacol Sin</source>. <year>2022</year>;<volume>43</volume>(<issue>11</issue>):<fpage>2993</fpage>&#8211;<lpage>3001</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41401-022-00908-4</pub-id><pub-id pub-id-type="pmid">35478244</pub-id><pub-id pub-id-type="pmcid">PMC9622805</pub-id></mixed-citation></ref><ref id="cit0046"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2019</year>;<volume>38</volume>(<issue>1</issue>):<fpage>184</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13046-019-1173-4</pub-id><pub-id pub-id-type="pmid">31053160</pub-id><pub-id pub-id-type="pmcid">PMC6500040</pub-id></mixed-citation></ref><ref id="cit0047"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jacquet</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dalonneau</surname><given-names>F</given-names></string-name>, et al</person-group>. <article-title>FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells</article-title>. <source>BMC Biol</source>. <year>2021</year>;<volume>19</volume>(<issue>1</issue>):<fpage>173</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12915-021-01103-3</pub-id><pub-id pub-id-type="pmid">34433435</pub-id><pub-id pub-id-type="pmcid">PMC8390225</pub-id></mixed-citation></ref><ref id="cit0048"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ferrari</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Terushkin</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis</article-title>. <source>J Cell Physiol</source>. <year>2009</year>;<volume>219</volume>(<issue>2</issue>):<fpage>449</fpage>&#8211;<lpage>458</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcp.21706</pub-id><pub-id pub-id-type="pmid">19180561</pub-id><pub-id pub-id-type="pmcid">PMC2749291</pub-id></mixed-citation></ref><ref id="cit0049"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Celastrol functions as an emerging manager of lipid metabolism: mechanism and therapeutic potential</article-title>. <source>Biomed Pharmacother</source>. <year>2023</year>;<volume>164</volume>:<fpage>114981</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114981</pub-id><pub-id pub-id-type="pmid">37285754</pub-id></mixed-citation></ref><ref id="cit0050"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Greenberg</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Kraemer</surname><given-names>FB</given-names></string-name>, et al</person-group>. <article-title>The role of lipid droplets in metabolic disease in rodents and humans</article-title>. <source>J Clin Invest</source>. <year>2011</year>;<volume>121</volume>(<issue>6</issue>):<fpage>2102</fpage>&#8211;<lpage>2110</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI46069</pub-id><pub-id pub-id-type="pmid">21633178</pub-id><pub-id pub-id-type="pmcid">PMC3104768</pub-id></mixed-citation></ref><ref id="cit0051"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hagberg</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Spalding</surname><given-names>KL</given-names></string-name></person-group>. <article-title>White adipocyte dysfunction and obesity-associated pathologies in humans</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2024</year>;<volume>25</volume>(<issue>4</issue>):<fpage>270</fpage>&#8211;<lpage>289</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41580-023-00680-1</pub-id><pub-id pub-id-type="pmid">38086922</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>